GLWL is conducting a Phase 2 clinical trial to to evaluate the efficacy, safety, and pharmacokinetics of GLWL-01 in treating hyperphagia in patients with PWS.

Participants will be assigned to one of two treatment sequences (GLWL-01/Placebo or Placebo/GLWL-01), with each sequence consisting of two treatment periods separated by a washout period. For more detailed information including inclusion/exclusion criteria, please click here.

Vanderbilt University Medical Center
Contact Margo Black at 615-343-5846 or

Alberta Diabetes Institute, University of Alberta
Contact: Kristie Dehaan  at 780-492-1095 or